Brain Blood Vessel Responses to Changes in Blood Flow
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age55-69
SponsorUniversity of Wisconsin, Madison
About this trial
Brain blood flow will be measured during a simulated postural change test and while breathing increased levels of carbon dioxide using magnetic resonance imaging.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Between the ages of 55-69 years
Have a BMI less than or equal to 34.5 kg/m2
Nonsmoker
are less than 72 in (182.88 cm) height
Disqualifiers
Diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD)
History or evidence of hepatic disease, hematological disease, or peripheral vascular disease; severe kidney injury requiring hemodialysis
History of cardiovascular disease including: severe congestive heart failure, coronary artery disease, ischemic heart disease (stents, coronary artery bypass grafts) and tachycardia
Uncontrolled hypertension
Trial design
Design model
Single group
Treatments tested in this trial
MRI
DeviceParticipants will undergo an MRI scan while performing breathing and a simulated postural change task.
Prazosin
DrugA dose of prazosin will be administered based on body weight.
Placebo
DrugOral placebo
Treatment groups
36 Participants
are divided into 1 treatment groupGroup A: Middle-Aged AdultsExperimental treatment 3 interventions
Trial outcomes
Primary outcomes
1
Change in blood flow
The change in intracranial blood flow during breathing and simulated postural change tasks will be measured with MRI
Time frame
Two study visits, up to 240 minutes2
Change in blood velocity
The change in blood velocity during breathing and simulated postural change tasks will be measured with MRI.
Time frame
Two study visits, up to 240 minutesSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Wisconsin, Madison
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Source ClinicalTrials.gov